Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.6% - Here's Why

Key Points

• Capricor Therapeutics jumped about 6.6% to $32.12 on Thursday, but trading was thin — roughly 184,252 shares changed hands, down ~87% from its average daily volume.
• Analyst sentiment is largely positive: nine Buy ratings vs one Sell, a consensus rating of Moderate Buy and an average price target of $46.09, with individual targets as high as $63.
• Company insiders have been selling recently — the CFO and a director executed large sales, and insiders sold 140,000 shares (~$4.27M) in the last quarter, though they still own 10.5% of the stock.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) was up 6.6% during trading on Thursday . The stock traded as high as $31.02 and last traded at $32.1220. Approximately 184,252 shares changed hands during trading, a decline of 87% from the average daily volume of 1,370,198 shares. The stock had previously closed at $30.12.

Wall Street Analysts Forecast Growth

CAPR has been the topic of a number of analyst reports. Cantor Fitzgerald set a $62.00 price objective on shares of Capricor Therapeutics and gave the company an "overweight" rating in a report on Friday, March 13th. Piper Sandler reissued an "overweight" rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Wall Street Zen cut Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, January 11th. B. Riley Financial upped their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a "buy" rating in a research report on Friday, March 13th. Finally, iA Financial set a $48.00 price objective on Capricor Therapeutics in a report on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $46.09.

Capricor Therapeutics Trading Up 5.3%

The firm's fifty day moving average price is $27.04 and its 200-day moving average price is $18.74. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -14.06 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). On average, sell-side analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Insider Transactions at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 25,000 shares of the business's stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total value of $753,250.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares of the company's stock, valued at approximately $247,758.99. The trade was a 75.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Karimah Es Sabar sold 53,735 shares of the company's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $31.03, for a total value of $1,667,397.05. The disclosure for this sale is available in the SEC filing. Insiders have sold 140,000 shares of company stock worth $4,269,012 in the last quarter. Insiders own 10.50% of the company's stock.

Institutional Investors Weigh In On Capricor Therapeutics

Large investors have recently modified their holdings of the company. Royal Bank of Canada increased its position in Capricor Therapeutics by 12.4% in the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company's stock valued at $146,000 after acquiring an additional 557 shares during the period. ACT Capital Management LLC acquired a new stake in Capricor Therapeutics during the 4th quarter worth approximately $43,000. Nuveen LLC lifted its position in Capricor Therapeutics by 2.1% during the 4th quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company's stock worth $2,625,000 after acquiring an additional 1,878 shares during the period. State of Wyoming grew its stake in shares of Capricor Therapeutics by 76.0% in the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company's stock valued at $128,000 after purchasing an additional 1,913 shares during the last quarter. Finally, GoalVest Advisory LLC acquired a new position in shares of Capricor Therapeutics in the fourth quarter valued at approximately $59,000. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.